The potential of DOT1L as a therapeutic target was also demonstrated for a subset of pancreatic adenocarcinomas, where high levels of the enzyme were found in 4.4% of 230 pancreatic tumors analyzed. This evidence concerns the gene DOT1L and pancreatic neoplasm.